Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate.
about
Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity DisorderBupropion for Attention Deficit Hyperactivity Disorder (ADHD) in adultsSafety of stimulant treatment in attention deficit hyperactivity disorder: Part I.Safety of stimulant treatment in attention deficit hyperactivity disorder: part II.Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulantsAmfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment optionsNew methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.An observational study of response heterogeneity in children with attention deficit hyperactivity disorder following treatment switch to modified-release methylphenidate.Attention-deficit-hyperactivity disorder: an update.Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder.Mindfulness Meditation Improves Mood, Quality of Life, and Attention in Adults with Attention Deficit Hyperactivity Disorder.Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA studyMethylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate.Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management.A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.Methylphenidate, cognition, and epilepsy: A double-blind, placebo-controlled, single-dose study.Bupropion for attention deficit hyperactivity disorder (ADHD) in adults.Methylphenidate, cognition, and epilepsy: A 1-month open-label trial.Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder.Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder.
P2860
Q22241421-914AB5AE-E9EB-4EAA-AABF-4FA0E8B83F41Q24234795-9C0152B9-9829-4E08-B7FD-3B8FF5F24810Q30449130-C4549B35-01B8-4F30-B60D-09AFD5503E5DQ30451303-9A6CFF69-FA53-4661-BED9-41C5BF1DC292Q33746664-4B39F02E-4016-4C63-B68D-D50FA743A7B5Q34286130-E4797C0B-C1AB-4BE0-83CD-AB463E48E645Q34468658-AFC4DCDC-1BDB-43E4-B951-BF5F6DC20588Q34978342-EF929CB3-9C80-483F-9AA1-32FB8E057BE4Q34983475-E78BF5CB-8CA6-4DFE-8B78-B378968D85AFQ35575795-09D76C41-1B7F-4844-8DBD-CD64B15F738AQ35763060-684F403B-8695-4512-9DCD-872400690D3FQ36613827-B4D17CA3-E7D1-4A8E-853B-BFAFEA91A97EQ36687442-7DF8C8A9-155D-4638-B9F3-20A7E1552A68Q37023974-B90B28E5-F56A-4E62-84AA-4F42BD575935Q37190656-9B463182-CF40-4DFC-BD15-6370CA03A345Q38239633-879EFC3A-658D-4F8F-BB05-DE235FD13BD4Q38383007-410AE4B6-C358-4292-BF58-121ADD701888Q43075919-298DD407-1AA8-490C-BE79-E8A4D7DD2386Q46739996-639280F3-21A7-4DB0-A953-A3D145E17867Q47550540-445FCDBA-909F-4621-85AE-2B46E5B21F13Q50266015-60C50A0B-23CC-43A3-BCB3-2DE50646C5A1
P2860
Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Pharmacokinetic considerations ...... disorder with methylphenidate.
@ast
Pharmacokinetic considerations ...... disorder with methylphenidate.
@en
type
label
Pharmacokinetic considerations ...... disorder with methylphenidate.
@ast
Pharmacokinetic considerations ...... disorder with methylphenidate.
@en
prefLabel
Pharmacokinetic considerations ...... disorder with methylphenidate.
@ast
Pharmacokinetic considerations ...... disorder with methylphenidate.
@en
P1433
P1476
Pharmacokinetic considerations ...... disorder with methylphenidate.
@en
P2093
Mark L Wolraich
Melissa A Doffing
P304
P356
10.2165/00023210-200418040-00004
P577
2004-01-01T00:00:00Z
P6179
1000527689